A Phase IB Study of BYL719 plus Everolimus in Patients with Advanced Cancers

Protocol
14-097
Full Title
A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients with Advanced Solid Tumors, with Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients
Phase
I
Purpose

The purpose of this study is to find the highest dosage of a two-drug combination — everolimus and BYL719 — that can be given safely in patients with advanced cancers that are large or have spread and cannot be cured with standard therapies.

Everolimus is approved for treating several types of cancer. It works by blocking mTOR, a protein that some cancer cells need to grow. BYL719 is an investigational drug that inhibits PI3 kinase, an enzyme which fuels the growth of several types of cancer.

Laboratory studies suggest that giving everolimus and BYL719 together may be more effective than giving either drug alone. Both drugs are taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor that is large or has spread and cannot be cured with standard therapy.
  • At least 4 weeks must pass between completion of prior therapy and entry into the study, and patients must recover from any serious side effects.
  • Patients may not have had previous treatment with PI3 kinase or mTOR inhibitors.
  • Patients must be able to be walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Matthew G. Fury at 646-888-4233.

Disease(s)
Solid Tumors
Locations

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »